Results 21 to 30 of about 578,179 (195)

Switching immune signals on and off

eLife, 2015
Bruton's tyrosine kinase, an enzyme that is important for B cell function, can be activated in a number of ways.
Nam Chu, Philip A Cole
doaj   +1 more source

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors

Burns & Trauma, 2014
Tec family kinases, which include tyrosine kinase expressed in hepatocellular carcinoma (TEC), Bruton's tyrosine kinase (BTK), interleukin (IL)-2-inducible T-cell kinase (ITK), tyrosine-protein kinase (TXK), and bone marrow tyrosine kinase on chromosome ...
Le Qiu, Fei Wang, Sheng Liu, Xu-Lin Chen
doaj   +1 more source

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema [PDF]

JAAD Case Reports
Shannon Meledathu, BS, Paul Chu, MD, Tatyana Feldman, MD, Andre Henri Goy, MD, Rachel Kushner Rosenstein, MD, PhD   +4 more
doaj   +2 more sources

Deep evolutionary conservation of an intramolecular protein kinase activation mechanism [PDF]

, 2012
DYRK-family kinases employ an intramolecular mechanism to autophosphorylate a critical tyrosine residue in the activation loop. Once phosphorylated, DYRKs lose tyrosine kinase activity and function as serine/threonine kinases.
Cleghon Vaughn, Aman Singh (191216), Cleghon, V., Nathan Luebbering (191210), Sibbet Gary, Jingfen Han, Luebbering Nathan, Nathan Luebbering, Michael A J Ferguson, Singh, A., Aman Singh, Ferguson, M.A.J., Ferguson Michael A. J., Hong, W., Diego Miranda-Saavedra (36622), Michael A. J. Ferguson (166662), Jingfen Han, Han, J., Gary Sibbet (191221), Vaughn Cleghon (191224), Miranda-Saavedra Diego, Sibbet, G., Ferguson, M.A.J.; id_orcid, Han Jingfen, Miranda-Saavedra, D., Gary Sibbet, Luebbering, N., Diego Miranda-Saavedra, Michael A. J. Ferguson, Vaughn Cleghon, Singh Aman, Jingfen Han (191204)   +31 more
core   +1 more source

Mechanism of Covalent Binding of Ibrutinib to Bruton’s Tyrosine Kinase revealed by QM/MM Calculations [PDF]

, 2020
Ibrutinib is the first covalent inhibitor of Bruton’s tyrosine kinase (BTK) to be used in the treatment of B-cell cancers. Understanding the mechanism of covalent inhibition is crucial for the design of safer and more selective covalent inhibitors that ...
Angus, Voice, Adrian, Mulholland, Rebecca, Twidale, Herman, Van Vlijmen, Gary, Tresadern   +4 more
core   +1 more source

ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library. [PDF]

PLoS ONE, 2017
Bruton's Tyrosine Kinase (BTK) is a cytoplasmic protein tyrosine kinase with a fundamental role in B-lymphocyte development and activation. The nucleocytoplasmic shuttling of BTK is specifically modulated by the Ankyrin Repeat Domain 54 (ANKRD54) protein
Manuela O Gustafsson, Dara K Mohammad, Erkko Ylösmäki, Hyunseok Choi, Subhash Shrestha, Qing Wang, Beston F Nore, Kalle Saksela, C I Edvard Smith   +8 more
doaj   +1 more source

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

eJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi   +9 more
doaj   +1 more source

MOESM6 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

, 2019
Additional file 6: Figure S6. Autoreactive IgG and IgM does not correlate with disease progression. Fluorescence intensity for plasma autoreactive IgG (A) and IgM (B) does not correlate with decline in forced vital capacity (FVC) over 1-year period in IPF patients. Correlation coefficients were calculated using Spearmanâ s rank method.
Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Boorsma, Carian, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam   +13 more
openaire   +1 more source

Evolution of breast cancer therapeutics: Breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy [PDF]

, 2014
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). © 2014 Baishideng Publishing Group Inc.There have been significant improvements in the detection
Hussain, HA, Harvey, A
core   +1 more source

MOESM1 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

, 2019
Additional file 1: Figure S1. No changes of proportions of total B-cells between controls and IPF patients. Flow cytometric quantification of total B-cells (CD19+) in blood, lungs and lymph nodes (LN) as percentage of alive cells. For blood samples data also depicted as absolute number of B-cells per ml blood.
Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Boorsma, Carian, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam   +13 more
openaire   +1 more source